<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70577">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02013141</url>
  </required_header>
  <id_info>
    <org_study_id>0101</org_study_id>
    <nct_id>NCT02013141</nct_id>
  </id_info>
  <brief_title>An Open-Label Study of the Pharmacokinetics of a Single Dose of Telavancin in Pediatric Subjects Aged 1 to 17 Years</brief_title>
  <official_title>An Open-Label Study of the Pharmacokinetics of a Single Dose of Telavancin in Pediatric Subjects Aged 1 to 17 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, single-dose pharmacokinetic (PK) study.  Infants,
      children, and adolescents will receive a single 10 mg/kg dose of telavancin infused
      intravenously (IV) over 60 minutes
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pharmacokinetics- AUC</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics- Cmax</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics- Tmax</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics- t1/2</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics- CLp</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Gram-Positive Bacterial Infections</condition>
  <arm_group>
    <arm_group_label>Telavancin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telavancin</intervention_name>
    <arm_group_label>Telavancin</arm_group_label>
    <other_name>VIBATIV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subject is 1 to 17 years (inclusive) and has a height/length/weight (for subjects between
        12 and 23 months) or body mass index (BMI, for subjects 2 to 17 years) within the 5th to
        95th percentile (inclusive) for age and sex.

        Subject requires intravenous antibiotics for:

          -  Gram-positive bacterial infection OR

          -  prophylaxis of Gram-positive infection OR

          -  empiric therapy for suspected Gram-positive infection

        Exclusion Criteria:

        Subject has an estimated creatinine clearance &lt;50 mL/min/1.73 m2 (Schwartz formula).

        Subject has a history of allergies or hypersensitivities to glycopeptide antibiotics
        (e.g., vancomycin), telavancin, or the formulation excipients.

        Subject requires concomitant vancomycin treatment.

        -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Frederic Heerinckx</last_name>
    <phone>650-808-6400</phone>
    <email>Fheerinckx@theravance.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>TBD</name>
      <address>
        <city>TBD</city>
        <state>California</state>
        <zip>94080</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>TBD TBD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 16, 2013</lastchanged_date>
  <firstreceived_date>December 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gram positive bacteria</keyword>
  <keyword>Telavancin</keyword>
  <keyword>VIBATIV</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Pharmacokinetics</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Gram-Positive Bacterial Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
